Hørsholm,
The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, ExpreS2ion's breast cancer vaccine candidate, ES2B C001 HER2-cVLP, and ExpreS2ion's 34% stake in its joint venture with NextGen Vaccines, AdaptVac.
The full English version of the company-sponsored equity research report is attached to this press release, while the Swedish version is available on Analysguiden's website: https://www.aktiespararna.se/analysguiden/Hitta-Bolag/health-care/expres2ion-biotech-holding/analys.
Certified Adviser
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion
https://news.cision.com/expres2ion-biotechnologies/r/analysguiden-announces-new-research-report-with-the-target-price-for-expres2ion-increased-to-49-sek-,c3331040
https://mb.cision.com/Main/14402/3331040/1405616.pdf
https://mb.cision.com/Public/14402/3331040/bee515855d3aa11c.pdf
(c) 2021 Cision. All rights reserved., source